COLUMVI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COLUMVI (COLUMVI).
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
| Metabolism | Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose). |
| Half-life | Terminal half-life approximately 20 days (range 14-28 days), consistent with IgG1 monoclonal antibody clearance via intracellular catabolism. |
| Protein binding | No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner. |
| Volume of Distribution | Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space. |
| Bioavailability | Intravenous administration yields 100% bioavailability. |
| Onset of Action | Clinical response (tumor reduction) observed within 4-8 weeks of initiating therapy. |
| Duration of Action | Duration of action persists for months post-last dose due to prolonged half-life; median duration of response approximately 18 months in clinical trials. |
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or on dialysis. |
| Liver impairment | No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COLUMVI (COLUMVI).
| Breastfeeding | No data on presence in human milk, effects on the breastfed child, or milk production. Human IgG is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown. |
| Teratogenic Risk | COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose. |
■ FDA Black Box Warning
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
| Serious Effects |
None known.
| Precautions | ["Cytokine release syndrome (CRS), including serious or life-threatening reactions","Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS)","Infections, including serious and opportunistic infections","Tumor flare reaction","Embryo-fetal toxicity"] |
Loading safety data…
| Fetal Monitoring | Monitor for infusion-related reactions, cytokine release syndrome (CRS), and neurologic toxicity during and after infusion. Perform pregnancy testing prior to initiation. If used during pregnancy, monitor for fetal B-cell depletion and immune function at birth. Monitor thyroid function and electrolytes due to potential tumor lysis syndrome. No specific fetal monitoring patterns established. |
| Fertility Effects | No dedicated fertility studies conducted. Glofitamab targets CD20 on B cells and may affect reproductive tissues expressing CD20. Preclinical studies have not reported direct effects on male or female fertility, but B-cell depletion could theoretically impact ovarian function. Based on mechanism, potential for impairment of fertility due to immunomodulation. Advise patients of possible fertility concerns. |